Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Asset Writedowns and Impairment (2017 - 2022)

Historic Asset Writedowns and Impairment for United Therapeutics (UTHR) over the last 5 years, with Q4 2022 value amounting to $4.2 million.

  • United Therapeutics' Asset Writedowns and Impairment changed N/A to $4.2 million in Q4 2022 from the same period last year, while for Sep 2024 it was $4.2 million, marking a year-over-year decrease of 6250.0%. This contributed to the annual value of $3.6 million for FY2023, which is 6785.71% down from last year.
  • Per United Therapeutics' latest filing, its Asset Writedowns and Impairment stood at $4.2 million for Q4 2022.
  • United Therapeutics' Asset Writedowns and Impairment's 5-year high stood at $113.4 million during Q1 2021, with a 5-year trough of -$400000.0 in Q3 2019.
  • Moreover, its 4-year median value for Asset Writedowns and Impairment was $6.2 million (2020), whereas its average is $23.1 million.
  • The largest annual percentage gain for United Therapeutics' Asset Writedowns and Impairment in the last 5 years was 145000.0% (2020), contrasted with its biggest fall of 145000.0% (2020).
  • Quarter analysis of 4 years shows United Therapeutics' Asset Writedowns and Impairment stood at $8.8 million in 2019, then tumbled by 38.64% to $5.4 million in 2020, then surged by 2000.0% to $113.4 million in 2021, then crashed by 96.3% to $4.2 million in 2022.
  • Its Asset Writedowns and Impairment stands at $4.2 million for Q4 2022, versus $7.0 million for Q3 2022 and $113.4 million for Q1 2021.